SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.74-2.1%Dec 17 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: zeta1961 who wrote (11932)6/6/2004 12:11:02 PM
From: Biomaven  Read Replies (1) of 52153
 
Thanks Zeta - we much appreciate the "on-the-spot" reporting.

That Erbitux/radiation study does look extremely complex for a P3 - seems to me they should have done the multiple arms in a P2 and then picked the best for a P3. When you have multiple arms like that the statistics becomes much harder and the power drops.

Interesting that Erbitux seems to have had some success now in head and neck - that's what they started out doing before the colon cancer took front stage.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News